| Author, Year, Followup,a Pain Duration, Study Quality | Intervention | Population | Function and Pain Outcomes | Other Outcomes |
|---|---|---|---|---|
Abbott, 201347 9.75 months Duration of diagnosis: 2.6 years Fair | A. Manual therapy (n=54/24 hip OA): 7 manual therapy sessions in 9 weeks with 2 additional booster sessions B. Exercise (n=51/22 hip OA), 7 exercise sessions in 9 weeks with 2 additional booster sessions C. Usual care (n=51/23 hip OA) | A vs. B vs. C (total population, includes knee OA) Age: 67 vs. 67 vs. 66 years Female: 49% vs. 52% vs. 58% Percent knee OA: 56% vs. 57% vs. 55% Percent hip OA: 44% vs. 43% vs. 45% Percent both hip OA and knee OA: 22% vs. 20% vs. 26% Baseline WOMAC (0-240): 114.8 vs. 95.5 vs. 93.8 | A vs. B (hip OA only) 9.75 months WOMAC, mean change from baseline: −22.9 vs. −12.4, p=NR A vs. C (hip OA only) 9.75 months WOMAC, mean change from baseline: −22.9 vs. 6.6, p=NR | None |
Hoeksma, 2004193 3 and 6 months Duration of symptoms: NR Fair | A. Manual therapy (n=56): Sessions consisted of stretching followed by traction manipulation in each limited position (high velocity thrust technique). B. Exercise therapy (n=53): Sessions implemented exercises for muscle functions, muscle length, joint mobility, pain relief, and walking ability and were tailored to the specific needs of the patient. Instructions for home exercises were given. Both groups received 2 sessions per week for 5 weeks (9 sessions in total). | Age: 72 vs. 71 years Females: 68% vs. 72% Symptom duration of 1 month to 5 years: 76% vs. 81% Severe OA on radiography: 45% vs. 38% Baseline HHS (0-100): 54 vs. 53 Baseline pain at rest VAS (0-100): 22.5 vs. 23.0 Baseline pain walking VAS (0-100): 34.0 vs. 28.8 | A vs. B 3 months HHS: 68.4 vs. 56.0, adjusted difference 11.1, 95% CI 4.0 to 18.6 Pain at rest VAS: 19.1 vs. 26.9, adjusted difference −7.2, 95% CI −13.8 to −0.5 Pain walking VAS: 16.4 vs. 23.7, adjusted difference −12.1, 95% CI −22.9 to −2.5 6 months HHS: 70.2 vs. 59.7, adjusted difference 9.7, 95% CI 1.5 to 17.9 Pain at rest VAS: 14.0 vs. 21.6, adjusted difference −7.0, 95% CI −20.3 to 5.9 Pain walking VAS: 17.0 vs. 24.3, adjusted difference −12.7, 95% CI −24.0 to −1.9 | A vs. B 3 months SF-36 physical function (0-100): 45.3 vs. 46.6, adjusted difference −2.1, 95% CI −11.7 to 7.7 SF-36 role physical function: 25.4 vs. 29.8, adjusted difference −23.5 to 10.2 SF-36 bodily pain: 47.4 vs. 46.1, adjusted difference −3.2, 95% CI −13.1 to 6.8 6 months SF-36 physical function: 50.4 vs. 45.3, adjusted difference 3.1, 95% CI −4.1 to 10.5 SF-36 role physical function: 36.7 vs. 32.4, adjusted difference 2.2, 95% CI −16.8 to 21.1 SF-36 bodily pain: 51.4 vs. 49.9, adjusted difference −1.5, 95% CI −11.1 to 7.7 |
Unless otherwise noted, followup time is calculated from the end of the treatment period
From: Results
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.